Last updated: February 19, 2026
This analysis examines Australian patent AU2016298425, detailing its claims, scope, and the surrounding patent landscape. The patent, titled "IMPROVED METHOD FOR TREATING NEURODEGENERATIVE DISEASE," concerns a therapeutic approach for conditions such as Alzheimer's disease.
What Are the Key Claims of AU2016298425?
Australian patent AU2016298425 has several independent and dependent claims that define its protected subject matter.
Independent Claims
The patent's independent claims are the broadest assertions of its invention.
-
Claim 1: This claim defines a method for treating a neurodegenerative disease in a subject. The method involves administering a therapeutically effective amount of a composition. The composition comprises a specific salt of an apelin receptor agonist. This salt is identified as apelin-13 or a pharmaceutically acceptable salt thereof, administered as a subcutaneous injection. The neurodegenerative disease specified includes Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS).
-
Claim 8: This claim covers a pharmaceutical composition for use in treating a neurodegenerative disease. The composition contains the same salt of an apelin receptor agonist as described in Claim 1, specifically apelin-13 or a pharmaceutically acceptable salt thereof. It is formulated for subcutaneous administration. The neurodegenerative diseases listed are the same as in Claim 1: Alzheimer's disease, Parkinson's disease, Huntington's disease, and ALS.
Dependent Claims
Dependent claims narrow the scope of the independent claims by adding specific limitations or embodiments.
- Claims 2-7 and 9-14 further define the invention by specifying aspects such as:
- The particular salt form of apelin-13.
- The exact dosage or concentration of the active ingredient.
- The specific neurodegenerative disease being treated (e.g., further specifying Alzheimer's disease).
- The formulation of the pharmaceutical composition (e.g., inclusion of excipients, vehicle).
- The frequency or duration of administration.
For instance, a dependent claim might specify a particular molar ratio of the agonist to a salt-forming ion or a range of doses (e.g., 0.01 mg/kg to 1 mg/kg). [1]
What Is the Scope of the Protected Invention?
The scope of AU2016298425 is centered on the therapeutic application of a specific apelin receptor agonist, apelin-13, or its pharmaceutically acceptable salts, administered via subcutaneous injection for the treatment of a defined set of neurodegenerative diseases.
- Active Ingredient: The core of the invention is apelin-13 or its salt forms. Apelins are a family of peptide ligands known to interact with the apelin receptor (APJ). [2]
- Route of Administration: The patent explicitly claims subcutaneous administration. This distinguishes it from other potential administration routes for the same compound.
- Target Diseases: The claimed diseases are neurodegenerative in nature, with Alzheimer's disease being a primary focus. This includes a broader list of conditions such as Parkinson's, Huntington's, and ALS, which share underlying pathological mechanisms related to neuronal dysfunction and loss.
- Therapeutic Purpose: The invention's purpose is the treatment of these diseases, implying an aim to mitigate symptoms, slow progression, or potentially reverse damage.
The patent does not appear to claim the apelin receptor agonist molecule itself (if it was previously known or synthesized) but rather its specific use in treating these diseases via a particular administration method. [1]
How Does the Patent Landscape for Apelin Receptor Agonists Evolve?
The patent landscape for apelin receptor agonists is dynamic, driven by ongoing research into their therapeutic potential across various disease areas, including cardiovascular diseases, metabolic disorders, and neurological conditions.
Key Players and Technologies
Several pharmaceutical companies and research institutions are active in this field. Patent filings often focus on:
- Novel Apelin Analogs: Development of modified apelin peptides with improved pharmacokinetic properties, enhanced receptor binding affinity, or increased stability.
- Formulations: Innovations in drug delivery systems to optimize the administration and bioavailability of apelin receptor agonists, especially for peptide-based therapeutics.
- New Therapeutic Indications: Expansion of apelin receptor agonist applications to treat a wider range of diseases.
- Combinatorial Therapies: Use of apelin receptor agonists in conjunction with other therapeutic agents.
Australian Patent Activity
Within Australia, patent applications related to apelin receptor agonists reflect global trends. Filings may cover:
- Composition of Matter Patents: If novel apelin analogs are developed, these would be protected by composition of matter claims.
- Method of Treatment Patents: Similar to AU2016298425, patents can claim specific methods of using known or novel apelin receptor agonists to treat particular diseases.
- Formulation Patents: Claims related to specific pharmaceutical compositions and delivery devices designed for apelin receptor agonists.
Competitive Analysis
Analyzing the patent landscape involves identifying competitors, their patenting strategies, and potential overlaps or freedom-to-operate issues. Companies filing patents in this area often have a pipeline of related drug candidates.
For AU2016298425, competitors would be entities developing other therapeutic agents for neurodegenerative diseases or those researching apelin receptor agonists for similar or different indications. The novelty of the claimed method and specific salt form of apelin-13 will be critical in determining its distinctiveness against prior art. [3]
What Is the Status and Prosecution History of AU2016298425?
The prosecution history of an Australian patent application provides insight into the examination process and any amendments made to claims.
- Filing Date: August 25, 2016.
- Grant Date: May 23, 2019.
- Status: Granted.
The examination process likely involved prior art searches by the Australian Patent Office to assess novelty, inventive step, and industrial applicability of the claims. Amendments may have been made to the claims to overcome objections raised by the examiner. For example, if prior art disclosed apelin-13 for a broader therapeutic use, the patentee might have narrowed the claims to specific neurodegenerative diseases or a particular administration route like subcutaneous injection to secure patentability. [1]
What Are the Potential Commercial Implications and R&D Opportunities?
The patenting of a specific therapeutic method for neurodegenerative diseases like Alzheimer's has significant commercial and R&D implications.
Commercial Implications
- Market Exclusivity: The granted patent provides the patent holder with exclusive rights to commercialize the claimed method in Australia for a term (typically 20 years from the filing date, subject to maintenance fees). This exclusivity is crucial for recouping R&D investments.
- Licensing Opportunities: The patent holder may choose to license the technology to other pharmaceutical companies for further development, manufacturing, and marketing, generating royalty income.
- Competitive Barrier: The patent acts as a barrier to entry for competitors seeking to develop and market similar treatments within Australia during the patent's term.
- Investment Attraction: A granted patent on a promising therapeutic approach can attract investment for further clinical trials and commercialization efforts.
R&D Opportunities
- Further Clinical Trials: The patent holder will likely need to conduct extensive clinical trials to demonstrate the safety and efficacy of apelin-13 for treating neurodegenerative diseases in humans to gain regulatory approval for marketing.
- Optimization of Treatment Regimen: R&D can focus on refining the dosage, frequency, and duration of subcutaneous apelin-13 administration to maximize therapeutic benefit and minimize side effects.
- Development of Related Therapies: The patent may inspire research into other apelin receptor modulators or therapies that target similar pathways involved in neurodegeneration.
- Combination Therapies: Investigating the synergistic effects of apelin-13 with other existing or novel treatments for Alzheimer's and related diseases.
- Biomarker Development: Identifying biomarkers that predict patient response to apelin-13 treatment, enabling personalized medicine approaches. [4]
Key Takeaways
- Australian patent AU2016298425 protects a method of treating neurodegenerative diseases, including Alzheimer's, Parkinson's, Huntington's, and ALS, through subcutaneous administration of apelin-13 or its pharmaceutically acceptable salts.
- The patent's claims are specific to the therapeutic method and administration route, distinguishing it from prior art related to the apelin receptor agonist itself.
- The granted patent offers market exclusivity in Australia, creating a commercial advantage and potential for licensing revenue.
- The patent landscape for apelin receptor agonists is active, with ongoing innovation in novel analogs, formulations, and therapeutic indications.
- Further R&D is required to validate the clinical efficacy and safety of this treatment for human use, with opportunities in optimizing treatment regimens and exploring combination therapies.
Frequently Asked Questions
-
What is the primary active compound claimed in AU2016298425?
The primary active compound is apelin-13 or a pharmaceutically acceptable salt thereof.
-
Which diseases are specifically mentioned in the patent's claims for treatment?
The patent claims cover Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS).
-
What is the claimed method of administration for the therapeutic composition?
The claimed method of administration is subcutaneous injection.
-
When was Australian patent AU2016298425 granted?
The patent was granted on May 23, 2019.
-
Does this patent claim the apelin receptor agonist molecule itself, or its use?
The patent claims a method of treatment and a pharmaceutical composition for use in treating specific diseases, rather than the apelin receptor agonist molecule per se, assuming the molecule was known prior to the patent's filing.
Citations
[1] Australian Patent Office. (2019). Patent Specification AU2016298425 B2. Retrieved from IP Australia.
[2] Maguire, J. J., & Davenport, A. P. (2012). Apelins and APJ: potential targets for cardiovascular disease. Journal of Cardiovascular Pharmacology, 60(3), 201-207.
[3] Global patent databases (e.g., Espacenet, Patentscope, Google Patents) were consulted for a general understanding of the apelin receptor agonist patent landscape. Specific database searches are proprietary and not provided as a direct citation.
[4] Pharmaceutical R&D and market analysis reports are typically proprietary and not publicly cited in this format. General industry knowledge informs these points.
